These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15762772)

  • 1. Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia.
    Shi J; Pfister M; Jenkins SG; Chapel S; Barrett JS; Port RE; Howard D
    Clin Pharmacokinet; 2005; 44(3):317-29. PubMed ID: 15762772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens.
    Lodise TP; Preston S; Bhargava V; Bryskier A; Nusrat R; Chapel S; Rangaraju M; Drusano GL
    Diagn Microbiol Infect Dis; 2005 May; 52(1):45-52. PubMed ID: 15878442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
    Low DE; Brown S; Felmingham D
    Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.
    Shi J; Montay G; Bhargava VO
    Clin Pharmacokinet; 2005; 44(9):915-34. PubMed ID: 16122280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.
    Fogarty CM; Patel TC; Dunbar LM; Leroy BP
    BMC Infect Dis; 2005 May; 5():43. PubMed ID: 15927060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW; Brown SD
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
    Fogarty CM; Buchanan P; Aubier M; Baz M; van Rensburg D; Rangaraju M; Nusrat R
    Int J Infect Dis; 2006 Mar; 10(2):136-47. PubMed ID: 16183318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
    Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens.
    Stein GE; Schooley S; Tyrrell KL; Citron DM; Goldstein EJ
    Int J Antimicrob Agents; 2007 Jan; 29(1):39-43. PubMed ID: 17189093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
    Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
    Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
    Mathers Dunbar L; Hassman J; Tellier G
    Clin Ther; 2004 Jan; 26(1):48-62. PubMed ID: 14996517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
    Tessier PR; Mattoes HM; Dandekar PK; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
    Öbrink-Hansen K; Hardlei TF; Brock B; Jensen-Fangel S; Kragh Thomsen M; Petersen E; Kreilgaard M
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis.
    Buchanan P; Roos K; Tellier G; Rangaraju M; Leroy B
    Int J Antimicrob Agents; 2005 Mar; 25(3):237-46. PubMed ID: 15737519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.
    Carbon C; van Rensburg D; Hagberg L; Fogarty C; Tellier G; Rangaraju M; Nusrat R
    Respir Med; 2006 Apr; 100(4):577-85. PubMed ID: 16376537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.
    Hagberg L; Torres A; van Rensburg D; Leroy B; Rangaraju M; Ruuth E
    Infection; 2002 Dec; 30(6):378-86. PubMed ID: 12478329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.